SEC Form 4 · accession 0001209191-15-009472
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Corp Controller
Period of report
Feb 2, 2015
Accepted (ET)
Feb 4, 2015 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 2, 2015 | M | 1,125 | $37.86 | A | 18,312 | D | |
| Common StockF2,F3 | Feb 2, 2015 | S | 300 | $108.11 | D | 18,012 | D | |
| Common StockF3,F4 | Feb 2, 2015 | S | 668 | $109.89 | D | 17,344 | D | |
| Common StockF3,F5 | Feb 2, 2015 | S | 157 | $110.76 | D | 17,187 | D | |
| Common Stock | Feb 3, 2015 | M | 938 | $38.80 | A | 18,125 | D | |
| Common StockF3,F6 | Feb 3, 2015 | S | 438 | $107.04 | D | 17,687 | D | |
| Common StockF3,F7 | Feb 3, 2015 | S | 300 | $108.16 | D | 17,387 | D | |
| Common Stock | Feb 3, 2015 | S | 100 | $109.50 | D | 17,287 | D | |
| Common Stock | Feb 3, 2015 | S | 100 | $111.32 | D | 17,187 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8 | $37.86 | Feb 2, 2015 | M | 1,125 | D | — | Feb 1, 2022 | Common Stock | 1,125 | 4,500 | D |
| Stock Option (right to buy)F9 | $38.80 | Feb 3, 2015 | M | 938 | D | — | Feb 2, 2021 | Common Stock | 938 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $108.11 (range $107.94 to $108.22).
- F3Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $109.89 (range $109.51 to $110.42).
- F5Open market sales reported on this line occurred at a weighted average price of $110.76 (range $110.74 to $110.80).
- F6Open market sales reported on this line occurred at a weighted average price of $107.04 (range $106.77 to $107.45).
- F7Open market sales reported on this line occurred at a weighted average price of $108.16 (range $108.03 to $108.40).
- F8The option vests in 16 quarterly installments from 02/02/2012.
- F9Fully vested.